Arbutus Biopharma Corporation
ABUS
NGS
Sector: Healthcare
Industry: Biotechnology
1.88
USD
-0.04
(-2.08%)
Optionable: Yes Market Cap: 325 M 90-day average vol: 592,338
Previous close: 1.92 Open: 1.92 Bid: 1.88 Ask: 1.91
52 week range
1.87 3.15
Last updated: Wednesday 4th October 2023
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
🎉 Exciting news! 🎉
You are invited to join our Discord Channel.
Interact, learn, and grow with experts in the markets!
Join our DiscordMetrics
Valuation
Price per Sales TTM ($) | 83.67 |
Price per Book TTM ($) | 2.40 |
PE Ratio (TTM) | -4.00 |
Book Value per Share ($) | 0.80 |
5 Year PE Range | NA , NA |
Returns
7 Day Return | -3.09% | |
1 Month Return | -7.84% | |
3 Month Return | -16.81% | |
1 Year Return | -3.09% | |
3 Year Return | -42.33% | |
5 Year Return | -79.87% | |
YTD Return | -19.31% |
Risk
Custom Beta One Year | 0.79 |
Custom Beta Three Years | 1.04 |
Beneish M Score | -2.02 |
Altman Z Score | -5.49 |
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 36.99 |
14 Day SMA ($) | 1.98 |
14 Day EMA ($) | 1.98 |
Money Flow Index | 62.75 |
Average True Range | 0.07 |
50 Day SMA ($) | 2.05 |
200 Day SMA ($) | 2.49 |
ADX | 10.08 |
MACD | -0.13 |
Growth
Free Cash Flow QoQ Growth | 0.00% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 0.00% |
Revenue QoQ Growth | 0.00% |
EPS YoY Growth | 0.00% |
Profitability
Financials
ABUS Income Statement
Annual
| Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | Dec-22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| AccruedPreferredStockDividends | 911000.0 | 10 M | 11 M | 12 M | 12 M | |||||
| Basic EPS total | -0.92 | -1.8 | -1.34 | -7.24 | -1.56 | -1.21 | -0.46 | -1.0 | -0.83 | -0.46 |
| Basic weighted shares outstanding | 15 M | 22 M | 45 M | 53 M | 55 M | 55 M | 57 M | 76 M | 106 M | 151 M |
| Depreciation | 613000.0 | 529000.0 | 589000.0 | 1 M | 2 M | 2 M | 2 M | -2 M | -2 M | -1 M |
| Depreciation unreconciled | 613000.0 | 529000.0 | 589000.0 | 1 M | 2 M | 2 M | 2 M | 2 M | ||
| DepreciationAndAmortization | 613000.0 | 529000.0 | 589000.0 | 1 M | 2 M | 2 M | 2 M | -2 M | -2 M | -1 M |
| Diluted EPS total | -0.92 | -1.8 | -1.34 | -7.24 | -1.56 | -1.21 | -2.89 | -1.0 | -0.83 | -0.46 |
| Diluted weighted shares outstanding | 15 M | 22 M | 45 M | 53 M | 55 M | 79 M | 53 M | 76 M | 106 M | 151 M |
| Earnings from equity interest | -6 M | -23 M | -3 M | |||||||
| EarningsFromEquityInterestNetOfTax | -6 M | -23 M | -3 M | |||||||
| GainOnSaleOfSecurity | 25 M | 14000.0 | -164000.0 | -2 M | ||||||
| GeneralAndAdministrativeExpense | 6 M | 9 M | 26 M | 39 M | 16 M | 16 M | 18 M | 15 M | 17 M | 18 M |
| Gross operating profit | 15 M | 15 M | 25 M | 1 M | 11 M | 6 M | 6 M | 7 M | 11 M | 39 M |
| ImpairmentOfCapitalAssets | 138 M | 22 M | ||||||||
| Income before tax | -14 M | -39 M | -77 M | -489 M | -109 M | -61 M | -166 M | -64 M | -76 M | -67 M |
| Income restructuring and M&A | 56 M | 109 M | 5 M | 156000.0 | 64000.0 | |||||
| Income taxes | -1150.0 | -3 M | -16 M | -105 M | -24 M | -4 M | -13 M | -622000.0 | -4 M | 4 M |
| Interest income | 540000.0 | 853000.0 | -96000.0 | 823000.0 | 179000.0 | -9 M | 2 M | 741000.0 | 127000.0 | 2 M |
| InterestExpenseNonOperating | 261000.0 | 226000.0 | 2 M | 4 M | 3 M | 2 M | ||||
| MiscOtherSpecialCharges | -4 M | -10 M | 3 M | 530000.0 | -22000.0 | |||||
| Net income from total operations | -14 M | -39 M | -61 M | -384 M | -84 M | -96 M | -154 M | -64 M | -76 M | -72 M |
| NetIncomeCommonStockholders | -14 M | -39 M | -61 M | -384 M | -85 M | -106 M | -165 M | -76 M | -89 M | -72 M |
| NetIncomeContinuousOperations | -14 M | -39 M | -61 M | -384 M | -84 M | -96 M | -154 M | -64 M | -76 M | -72 M |
| NetIncomeDiscontinuousOperations | 3 M | |||||||||
| NetNonOperatingInterestIncomeExpense | 540000.0 | 853000.0 | -96000.0 | 823000.0 | -82000.0 | -9 M | 3000.0 | -3 M | -3 M | 466000.0 |
| NonRecurringOperationExpense | 6 M | |||||||||
| Operating income | -12 M | -33 M | -54 M | -100 M | -70 M | -70 M | -71 M | -57 M | -72 M | -63 M |
| Operating income before depreciation (EBITDA) | -13 M | -38 M | -77 M | -488 M | -106 M | -59 M | -163 M | -58 M | -71 M | -64 M |
| OperatingExpense | -28 M | -48 M | -127 M | -493 M | -122 M | -96 M | -150 M | -65 M | -85 M | -104 M |
| Other income net | 4 M | 11 M | 45 M | 253 M | 41 M | 15 M | 66 M | 3 M | 2 M | 4 M |
| OtherGandA | 6 M | 9 M | 26 M | 39 M | 16 M | 16 M | 18 M | 15 M | 17 M | 18 M |
| OtherImpairmentOfCapitalAssets | 39 M | 253 M | 41 M | 15 M | 44 M | |||||
| OtherTaxes | -43000.0 | -52000.0 | -196000.0 | -145000.0 | -183000.0 | -18000.0 | ||||
| OtherunderPreferredStockDividend | 911000.0 | 10 M | 11 M | 12 M | 12 M | |||||
| PreferredStockDividends | 911000.0 | 10 M | 11 M | 12 M | 12 M | |||||
| ProvisionForGainLossOnDisposal | 3 M | |||||||||
| RentAndLandingFees | 6 M | 9 M | 26 M | 39 M | 16 M | 16 M | 18 M | 15 M | 17 M | 18 M |
| Research & development expense | 21 M | 39 M | 52 M | 61 M | 63 M | 58 M | 58 M | 49 M | 66 M | 84 M |
| ResearchExpense | 21 M | 39 M | 52 M | 61 M | 63 M | 58 M | 58 M | 49 M | 66 M | 84 M |
| RestructringAndMnAIncome | 56 M | 109 M | 5 M | 156000.0 | 64000.0 | |||||
| SalariesAndWages | -903.0 | -3 M | -22 M | -39 M | -15 M | -6 M | -7 M | -6 M | -6 M | -7 M |
| Selling Gen & administrative expense | 6 M | 9 M | 26 M | 39 M | 16 M | 16 M | 18 M | 15 M | 17 M | 18 M |
| Special income/charges | -56 M | -109 M | -138 M | -5 M | -29 M | -64000.0 | ||||
| Total Income available for interest expense (EBIT) | -14 M | -39 M | -77 M | -489 M | -108 M | -61 M | -164 M | -60 M | -74 M | -65 M |
| Total common shares outstanding | 22 M | 47 M | 55 M | 55 M | 55 M | 56 M | 69 M | 96 M | 149 M | 163 M |
| Total net income | -14 M | -39 M | -61 M | -384 M | -84 M | -96 M | -154 M | -64 M | -76 M | -72 M |
| Total ordinary shares | 168 M | 168 M | 168 M | 168 M | 168 M | 168 M | 168 M | 168 M | 168 M | 168 M |
| Total revenues | 15 M | 15 M | 25 M | 1 M | 11 M | 6 M | 6 M | 7 M | 11 M | 39 M |
| TotalExpenses | -28 M | -48 M | -127 M | -493 M | -122 M | -96 M | -150 M | -65 M | -85 M | -104 M |
| TotalRevenue | 15 M | 15 M | 23 M | 1 M | 11 M | 6 M | 6 M | 7 M | 11 M | 39 M |
Call: 1-877-778-8358
Welcome! I'm Ankur, the founder/CEO of MarketXLS. With over six years of experience, I've helped 2500+ customers implement personalized investment research strategies and monitoring systems in Excel.
Implement “your own” investment strategies in Excel with thousands of MarketXLS functions and Templates.
Get started today
Get started today